Nama's AI scorecard currently rates MannKind Sell (1.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does MNKD report earnings?

MannKind's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.06.

What is the MNKD price target?

The median analyst price target from 9 analysts is $8.00, with a range of $4.75 – $13.00.

Is MNKD Shariah compliant?

Nama's AAOIFI-style screen reads MannKind as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

MannKind (MNKD)

Healthcare · Biotechnology · NASDAQ

MannKind (MNKD) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.25B and a free-cash-flow yield of 1.0%. Over the most recent reported fiscal year, revenue grew 22.2% and free cash flow per share fell 62.3%. Nama's AI scorecard rates it Sell, 1.5 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Sell · 1.5/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Trailing · -39.5% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-48.9%

How far the last close sits under the highest price of the past five years.

Market cap	$1.25B
Trailing P/E	—
Price / book	—
Price / sales	3.2
FCF yield	1.0%
Dividend yield	—
Gross margin	75.4%
Operating margin	1.9%
Net margin	-11.1%
Revenue growth (YoY)	+22.2%
Revenue growth (3-yr annual)	+51.8%
EPS growth (YoY)	+10.0%
FCF/share growth (YoY)	-62.3%
Beta	1.1
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

MNKD earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $0.06). Beat the EPS estimate in 0 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	-$0.01	-$0.01	+0.0%	—
Q2 2026	Aug 5, 2026	-$0.01	$0.02	-150.0%	$109.38M
Q1 2026	May 6, 2026	-$0.02	$0.01	-300.0%	$90.17M
Q4 2025	Feb 26, 2026	-$0.05	$0.01	-600.0%	$111.95M

MNKD analyst price target

Median target $8.00 from 9 analysts, ranging $4.75 – $13.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live MNKD data on Nama Insights →

MNKD FAQ

Is MNKD a buy?: Nama's AI scorecard currently rates MannKind Sell (1.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does MNKD report earnings?: MannKind's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.06.
What is the MNKD price target?: The median analyst price target from 9 analysts is $8.00, with a range of $4.75 – $13.00.
Is MNKD Shariah compliant?: Nama's AAOIFI-style screen reads MannKind as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.